Brief: Rappta Therapeutics Enters Into A Global License Agreement With Springworks Therapeutics
13/01/2025 11:53
Jan 13 (Reuters) - SpringWorks Therapeutics Inc
SWTX.O :
* RAPPTA THERAPEUTICS ENTERS INTO A GLOBAL LICENSE AGREEMENT
WITH
SPRINGWORKS THERAPEUTICS FOR A PRE-CLINICAL FIRST-IN-CLASS
MOLECULAR GLUE TARGETING PP2A
* FINANCIALS INCLUDE A $13 MILLION UPFRONT PAYMENT AND
POTENTIAL
MILESTONES PAYMENTS
Source text: ID:nPrewgG5da
Further company coverage: SWTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on SpringWorks Therapeutics
See all newsBrief: Merck KGaA Completes Acquisition Of Springworks Therapeutics
Brief: Springworks Therapeutics Expects Nirogacestat Decision From European Commission In Q3
Brief: EMA's CHMP Re-Examines Rejection Of Kisunla For Early Alzheimer’S Treatment
Brief: SpringWorks Therapeutics Receives Positive CHMP Opinion for Mirdametinib for the Treatment of Adult and Pediatric Patients with NF1-PN
Brief: SpringWorks Therapeutics Receives Positive CHMP Opinion For Mirdametinib For The Treatment Of Adult And Pediatric Patients With NF1-PN